KZR Insider Trading
Insider Ownership Percentage: 9.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $3,874.40
Kezar Life Sciences Insider Trading History Chart
This chart shows the insider buying and selling history at Kezar Life Sciences by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Kezar Life Sciences Share Price & Price History
Current Price: $4.60
Price Change: ▲ Price Increase of +0.09 (2.00%)
As of 04/2/2025 05:00 PM ET
Kezar Life Sciences Insider Trading History
Kezar Life Sciences Institutional Trading History
Data available starting January 2016
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Read More on Kezar Life Sciences
Volume
8,665 shs
Average Volume
30,680 shs
Market Capitalization
$33.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.49
Who are the company insiders with the largest holdings of Kezar Life Sciences?